Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients

Table 5

Complications.

	Bevacizumab group (𝑛=79 patients)	Ranibizumab group (𝑛=74 patients)	P value
Punctuate keratitis	10 (12.6%)	11 (14.8%)	0.7
Subconjunctival Hemorrhage	7 (8.8%)	8 (10.8%)	0.5
Mild transient Anterior uveitis	5 (6.3%)	2 (2.7%)	0.1